Genmab A/S

詳細情報 Genmab A/S 企業名

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

企業情報

企業コードGMAB

会社名Genmab A/S

上場日Oct 01, 2000

最高経営責任者「CEO」Dr. Jan G.J. Van De Winkel, Ph.D.

従業員数2682

証券種類Ordinary Share

決算期末Oct 01

本社所在地Carl Jacobsens Vej 30

都市VALBY

証券取引所OMX Nordic Exchange Copenhagen A/S

国Denmark

郵便番号2500

電話番号4570202728

ウェブサイトhttps://www.genmab.com/

企業コードGMAB

上場日Oct 01, 2000

最高経営責任者「CEO」Dr. Jan G.J. Van De Winkel, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.

Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

--

Dr. Judith V. Klimovsky, M.D.

Executive Vice President, Chief Development Officer

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Mr. Christopher Cozic

Executive Vice President, Chief People Officer

--

Mr. Martin Schultz

Non-Independent Director, Employee Elected

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

Dr. Paolo Paoletti, M.D.

Independent Director

--

Dr. Jan G.J. Van De Winkel, Ph.D.

President, Chief Executive Officer

--

Ms. Mijke Zachariasse, Ph.D.

Non-Independent Director, Employee Elected

--

Ms. Elizabeth A. O'farrell

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.

Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

--

Dr. Judith V. Klimovsky, M.D.

Executive Vice President, Chief Development Officer

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Mr. Christopher Cozic

Executive Vice President, Chief People Officer

--

Mr. Martin Schultz

Non-Independent Director, Employee Elected

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Royalties

589.00M

82.38%

Net product sales

75.00M

10.49%

Reimbursement income

23.00M

3.22%

Collaboration revenue

16.00M

2.24%

Milestone payments

12.00M

1.68%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

Royalties

589.00M

82.38%

Net product sales

75.00M

10.49%

Reimbursement income

23.00M

3.22%

Collaboration revenue

16.00M

2.24%

Milestone payments

12.00M

1.68%

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

AllianceBernstein L.P.

2.32%

Orbis Investment Management Ltd.

0.90%

Citadel Advisors LLC

0.70%

Two Sigma Investments, LP

0.61%

BlackRock Institutional Trust Company, N.A.

0.47%

Other

95.00%

株主統計

比率

AllianceBernstein L.P.

2.32%

Orbis Investment Management Ltd.

0.90%

Citadel Advisors LLC

0.70%

Two Sigma Investments, LP

0.61%

BlackRock Institutional Trust Company, N.A.

0.47%

Other

95.00%

種類

株主統計

比率

Investment Advisor/Hedge Fund

4.27%

Investment Advisor

2.99%

Hedge Fund

2.45%

Research Firm

0.51%

Pension Fund

0.03%

Bank and Trust

0.02%

Venture Capital

0.01%

Other

89.73%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

498

64.99M

10.26%

-6.57M

2025Q1

515

65.99M

10.42%

-5.32M

2024Q4

512

61.76M

9.33%

+621.44K

2024Q3

493

53.46M

8.41%

-4.14M

2024Q2

495

49.90M

7.86%

-6.30M

2024Q1

501

49.04M

7.53%

-7.16M

2023Q4

490

47.86M

7.32%

-6.37M

2023Q3

479

48.54M

7.43%

+204.98K

2023Q2

467

42.76M

6.55%

-5.77M

2023Q1

481

44.22M

6.78%

-6.32M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

AllianceBernstein L.P.

14.73M

2.32%

-210.07K

-1.41%

Mar 31, 2025

Orbis Investment Management Ltd.

5.71M

0.9%

+2.90M

+102.83%

Mar 31, 2025

Citadel Advisors LLC

4.43M

0.7%

+1.33M

+43.16%

Mar 31, 2025

Two Sigma Investments, LP

3.87M

0.61%

+513.60K

+15.29%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

2.95M

0.47%

-433.32K

-12.82%

Mar 31, 2025

Harding Loevner LP

2.88M

0.45%

+637.43K

+28.41%

Mar 31, 2025

Renaissance Technologies LLC

2.26M

0.36%

+336.20K

+17.45%

Mar 31, 2025

Marshall Wace LLP

2.18M

0.34%

+1.06M

+94.38%

Mar 31, 2025

Brandywine Global Investment Management, LLC

1.72M

0.27%

+97.63K

+6.03%

Mar 31, 2025

First Trust Advisors L.P.

1.71M

0.27%

+65.52K

+3.98%

Mar 31, 2025

詳細を見る

22.015USD

Genmab A/S

22.015

概要

企業名

金融